HEPATITIS

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

M-F Yuen, H-J Yuan, D K-H Wong, J C-H Yuen, W-M Wong, A O-O Chan, B C-Y Wong, K-C Lai, C-L Lai

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Correspondence to:
Professor C-L Lai
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Hong Kong, China; hrmelcl{at}hkucc.hku.hk

Background: Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for setting up treatment criteria.

Aim: To determine risk factors for the development of complications in Asian CHB patients.

Patients and methods: A total of 3233 Chinese CHB patients (mean follow up 46.8 months) were monitored for liver biochemistry, viral serology, hepatitis B virus (HBV) DNA levels, acute exacerbation, hepatitis B e antigen (HBeAg) seroconversion, and development of cirrhotic complications and hepatocellular carcinoma.

Results: Median age for HBeAg seroconversion and development of complications was 35 years and 57.2 years, respectively. Patients with alanine aminotransferase (ALT) levels of 0.5–1 times the upper limit of normal (ULN) and 1–2x ULN had an increased risk for the development of complications compared with patients with ALT levels <0.5x ULN (p<0.0001 for both). HBeAg/antibody to hepatitis B e antigen status, and number of episodes, duration, and peak ALT levels of acute exacerbations were not associated with an increased risk of complications. In patients with complications, 43.6% had HBV DNA levels less than 1.42x10⁵ copies/ml. Male sex, stigmata of chronic liver disease, old age, low albumin, and high fetoprotein levels on presentation were independently associated with increased cumulative risk of complications. Male sex, presence of hepatitis symptoms, old age, low albumin level, and presence of complications on presentation were independently associated with shorter survival.

Conclusion: Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5–2x ULN, is the most likely pathway for the development of complications in Asian CHB patients.

Abbreviations: CHB, chronic hepatitis B; HBV, hepatitis B virus; ALT, alanine aminotransferase; ULN, upper limit of normal; HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; SBP, spontaneous bacterial peritonitis; anti-HBe, antibody to hepatitis B e antigen; AFP, fetoprotein; PCR, polymerase chain reaction

Keywords: HBeAg seroconversion; alanine aminotransferase; cirrhosis related complications; hepatocellular carcinoma; survival

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Do baseline ALT levels predict complications of chronic hepatitis B? • Authors’ reply

T-I Huo, J-C Wu, S-D Lee, M-F Yuen, and C-L Lai
Gut 2006 55: 745-746. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Chan, H. L.-Y., Wong, V. W.-S., Wong, G. L.-H., Chim, A. M.-L., Lai, L. H., Sung, J. J.-Y. (2009). Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. J. Clin. Microbiol. 47: 1830-1836 [Abstract] [Full Text]  
• SHERMAN, M. (2009). Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleveland Clinic Journal of Medicine 76: S6-S9 [Abstract] [Full Text]  
• Lai, C.-L., Yuen, M.-F. (2008). Chronic Hepatitis B -- New Goals, New Treatment. NEJM 359: 2488-2491 [Full Text]  
• Singh, N. A., Reau, N. (2008). Management of hepatitis B virus. J Antimicrob Chemother 62: 224-228 [Abstract] [Full Text]  
• Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., Naoumov, N. V., Di Bisceglie, A. M., Zeuzem, S., Moon, Y. M., Goodman, Z., Chao, G., Constance, B. F., Brown, N. A., the Globe Study Group, (2007). Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. NEJM 357: 2576-2588 [Abstract] [Full Text]  
• Lai, C.-L., Yuen, M.-F. (2007). The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. ANN INTERN MED 147: 58-61 [Abstract] [Full Text]  
• Degertekin, B., Lok, A. S.F. (2007). When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. ANN INTERN MED 147: 62-64 [Full Text]  
• Sherman, M (2005). Predicting survival in hepatitis B. Gut 54: 1521-1523 [Full Text]